KBC Group’s AstraZeneca AZN Stock Holding History

KBC Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-808	Closed	-$108K	–	1857
2023 Q4	$108K	Hold	808	–	–	﹤0.01%	1032
2023 Q3	$109K	Hold	808	–	–	﹤0.01%	974
2023 Q2	$115K	Sell	808 -1,038	-56%	-$153K	﹤0.01%	1128
2023 Q1	$256K	Sell	1,846 -120	-6%	-$16.1K	﹤0.01%	904
2022 Q4	$266K	Sell	1,966 -15,174	-89%	-$1.9M	﹤0.01%	891
2022 Q3	$1.88M	Buy	17,140 +6,959	+68%	+$883K	0.01%	558
2022 Q2	$1.34M	Buy	+10,181	New	+$1.34M	0.01%	616
2021 Q3	–	Sell	-1,105	Closed	-$132K	–	1294
2021 Q2	$132K	Buy	+1,105	New	+$121K	﹤0.01%	1138
2019 Q1	–	Sell	-1,000	Closed	-$76K	–	1410
2018 Q4	$76K	Hold	1,000	–	–	﹤0.01%	1193
2018 Q3	$79K	Hold	1,000	–	–	﹤0.01%	1306
2018 Q2	$70K	Buy	+1,000	New	+$71.9K	﹤0.01%	1205

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

KBC Group's AZN Position: Q1 2024 in Review

KBC Group sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 808 shares — an estimated $108K sold.

KBC Group first reported a position in AZN in Q2 2018 and held it in 11 quarters. The position peaked at $1.88M in Q3 2022. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

KBC Group reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
KBC Group sold 808 AstraZeneca shares in Q1 2024, an estimated $108K.
KBC Group first reported a position in AstraZeneca in Q2 2018 and held it in 11 quarters.
KBC Group's AstraZeneca position peaked at $1.88M in Q3 2022.
1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on KBC Group's 13F filing for Q1 2024, filed 8 May 2024.